EL7.AI
Mergers & AcquisitionsMediumUpdated×2•Originally published 19 October 2026•Updated 19 October 2026•
1 min read

Merck KGaA Offers $20 Per Share to Acquire Silence Therapeutics

Key Facts

1Germany's Merck KGaA has agreed to acquire Silence Therapeutics in an all-cash transaction.

Germany's Merck KGaA is offering $20 in cash for each American depositary share of Silence Therapeutics as part of its acquisition agreement. Seeking Alpha reported that the offer price represents more than double the previous closing price of the biotechnology firm.

Silence Therapeutics (SLN) closed at $8.68 on October 16, 2026, placing the $20 offer at a significant premium. On the same date, Merck KGaA (MKGAF) shares closed at $161.80, as the German group moves to integrate Silence Therapeutics' gene silencing (siRNA) capabilities into its medical pipeline.

Latest Updates · 1

  1. Notable·

    Update: Silence Therapeutics stock surged 125% following the acquisition announcement. The sharp rally reflects the market's reaction to the $20 per share premium offered by Merck KGaA.